Philip Reigan

3.7k total citations
78 papers, 3.0k citations indexed

About

Philip Reigan is a scholar working on Molecular Biology, Oncology and Toxicology. According to data from OpenAlex, Philip Reigan has authored 78 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Molecular Biology, 17 papers in Oncology and 12 papers in Toxicology. Recurrent topics in Philip Reigan's work include Bioactive Compounds and Antitumor Agents (12 papers), Genomics, phytochemicals, and oxidative stress (11 papers) and Cancer therapeutics and mechanisms (8 papers). Philip Reigan is often cited by papers focused on Bioactive Compounds and Antitumor Agents (12 papers), Genomics, phytochemicals, and oxidative stress (11 papers) and Cancer therapeutics and mechanisms (8 papers). Philip Reigan collaborates with scholars based in United States, United Kingdom and Canada. Philip Reigan's co-authors include Donald S. Backos, Christopher J. Matheson, Steffanie L. Furtek, Dennis R. Petersen, David Ross, David Siegel, Colin T. Shearn, Christopher C. Franklin, Kristofer S. Fritz and Wenchang Guo and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Neuroscience and SHILAP Revista de lepidopterología.

In The Last Decade

Philip Reigan

75 papers receiving 2.9k citations

Peers

Countries citing papers authored by Philip Reigan

Since Specialization

Citations

This map shows the geographic impact of Philip Reigan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Reigan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Reigan more than expected).

Fields of papers citing papers by Philip Reigan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip Reigan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Reigan. The network helps show where Philip Reigan may publish in the future.

Co-authorship network of co-authors of Philip Reigan

This figure shows the co-authorship network connecting the top 25 collaborators of Philip Reigan. A scholar is included among the top collaborators of Philip Reigan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip Reigan. Philip Reigan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Small Molecule Modulators of AMP-Activated Protein Kinase (AMPK) Activity and Their Potential in Cancer Therapy 2025 ·Journal of Medicinal Chemistry ·John Strang, (unknown), (unknown), Philip Reigan	4
2	Neuroprotective efficacy of the glucocorticoid receptor modulator PT150 in the rotenone mouse model of Parkinson’s disease 2024 ·NeuroToxicology ·(unknown), Savannah M. Rocha, (unknown), Philip Reigan, (unknown), (unknown)	2
3	Evolutionary degeneration of septins into pseudoGTPases: impacts on a hetero-oligomeric assembly interface 2023 ·Frontiers in Cell and Developmental Biology ·Alya Hussain, (unknown), Philip Reigan, Michael A. McMurray	5
4	Auriculocondylar syndrome 2 results from the dominant-negative action of PLCB4 variants 2022 ·Disease Models & Mechanisms ·(unknown), Caleb Heffner, Timothy C. Cox, Michael L. Cunningham, Francisco A. Perez, Aaron M. Bauer, Philip Reigan, (unknown), Stephen A. Murray, David E. Clouthier	7
5	A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection 2022 ·Frontiers in Immunology ·Savannah M. Rocha, Anna C. Fagre, (unknown), Jason E. Cummings, Tawfik Aboellail, Philip Reigan, (unknown), (unknown), Katriana A. Popichak, Rebekah C. Kading, Tony Schountz, Neil D. Theise, Richard A. Slayden, Ronald B. Tjalkens	9
6	Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers 2019 ·Molecular Cancer Research ·Rebecca E. Schweppe, Nikita Pozdeyev, Laura A. Pike, Christopher Korch, Qiong Zhou, Sharon B. Sams, Vibha Sharma, Umarani Pugazhenthi, Christopher D. Raeburn, Maria Albuja‐Cruz, Philip Reigan, Daniel V. LaBarbera, Iñigo Landa, Jeffrey A. Knauf, James A. Fagin, Bryan R. Haugen	12
7	Isoxazolo[3,4-d]pyridazinones positively modulate the metabotropic glutamate subtypes 2 and 4 2018 ·Bioorganic & Medicinal Chemistry ·(unknown), Donald S. Backos, Philip Reigan, Hye Jin Kang, (unknown), (unknown), Nicholas R. Natale	1
8	Targeting WEE1 Kinase in Cancer 2016 ·Trends in Pharmacological Sciences ·Christopher J. Matheson, Donald S. Backos, Philip Reigan	306
9	Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma 2015 ·Cancer Immunology Research ·Andrea M. Griesinger, (unknown), Andrew M. Donson, Jean M. Mulcahy Levy, Vladimir Amani, Diane K. Birks, Lindsey M. Hoffman, Steffanie L. Furtek, Philip Reigan, Michael H. Handler, Rajeev Vibhakar, Nicholas K. Foreman	56
10	AIMing towards improved antitumor efficacy 2015 ·Bioorganic & Medicinal Chemistry Letters ·Matthew J. Weaver, (unknown), (unknown), Chun Li, (unknown), (unknown), Donald S. Backos, Philip Reigan, Howard D. Beall, Nicholas R. Natale	7
11	Inhibition of Wee1 Sensitizes Cancer Cells to Antimetabolite Chemotherapeutics In Vitro and In Vivo , Independent of p53 Functionality 2013 ·Molecular Cancer Therapeutics ·(unknown), Dmitry Baturin, (unknown), Susan Fosmire, (unknown), Christopher Korch, Philip Reigan, Christopher C. Porter	106
12	Identification of Functionally Relevant Lysine Residues That Modulate Human Farnesoid X Receptor Activation 2013 ·Molecular Pharmacology ·An–Qiang Sun, Yuhuan Luo, Donald S. Backos, Shuhua Xu, Natarajan Balasubramaniyan, Philip Reigan, Frederick J. Suchy	7
13	Manganese Superoxide Dismutase Regulates a Metabolic Switch during the Mammalian Cell Cycle 2012 ·Cancer Research ·Ehab H. Sarsour, Amanda L. Kalen, Zhen Xiao, Timothy D. Veenstra, Leena Chaudhuri, Sujatha Venkataraman, Philip Reigan, Garry R. Buettner, Prabhat C. Goswami	54
14	Characterization of 4-HNE Modified L-FABP Reveals Alterations in Structural and Functional Dynamics 2012 ·PLoS ONE ·Rebecca L. Smathers, Kristofer S. Fritz, James J. Galligan, Colin T. Shearn, Philip Reigan, Michael J. Marks, Dennis R. Petersen	53
15	Post-Translational Oxidative Modification and Inactivation of Mitochondrial Complex I in Epileptogenesis 2012 ·Journal of Neuroscience ·Kristen Ryan, Donald S. Backos, Philip Reigan, Manisha Patel	76
16	Mechanism‐Based Inhibition of Quinone Reductase 2 (NQO2): Selectivity for NQO2 over NQO1 and Structural Basis for Flavoprotein Inhibition 2011 ·ChemBioChem ·(unknown), Chao Yan, David Siegel, Marie A. Colucci, Matthew Jenner, Neil J. Oldham, Joe Gomez, Philip Reigan, Yazhuo Li, (unknown), David Ross, Christopher J. Moody	18
17	Xanthine oxidase-activated prodrugs of thymidine phosphorylase inhibitors 2007 ·European Journal of Medicinal Chemistry ·Philip Reigan, Abdul M Gbaj, Ian J. Stratford, Richard A. Bryce, Sally Freeman	15
18	Acrolein Inhibits Cytokine Gene Expression by Alkylating Cysteine and Arginine Residues in the NF-κB1 DNA Binding Domain 2007 ·Journal of Biological Chemistry ·Cherie Lambert, Jimei Li, Karen R. Jonscher, (unknown), Philip Reigan, Megan T. Quintana, Jean A. Harvey, Brian M. Freed	99
19	Molecular docking studies investigating the interaction of a series of benzoquinone ansamycin Hsp90 inhibitors with NAD(P)H:quinone oxidoreductase 1 (NQO1) 2006 ·Cancer Research ·Philip Reigan, Wenchang Guo, David Siegel, David Ross	1
20	Synthesis and enzymatic evaluation of xanthine oxidase-activated prodrugs based on inhibitors of thymidine phosphorylase 2004 ·Bioorganic & Medicinal Chemistry Letters ·Philip Reigan, Abdul M Gbaj, Edwin C. Chinje, Ian J. Stratford, Kenneth T. Douglas, Sally Freeman	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact